RGNX is focused on developing, commercializing and licensing recombinant adeno-associated virus gene therapy with a proprietary delivery platform to treat rare diseases. RGNX is commercializing gene therapy products administered directly into the body, or in vivo, based on a NAV Technology Platform. Its NAV Technology Platform is currently being applied in the development of 23 product candidates for a variety of diseases, Regenxbio said, with exclusive rights to over 100 patents and patent applications worldwide.
October 21, 2022
RegMed Investors’ (RMi) closing bell: no ladders needed; the tide went out and today came back in
October 20, 2022
RegMed Investors’ (RMi) closing bell: The upside didn’t last long after Wednesday’s extreme downside from an upside open
October 18, 2022
RegMed Investors’ (RMi) closing bell: a choppy sector session
October 17, 2022
RegMed Investors’ (RMi) closing bell: support levels are back for the oversold, although with low volume
October 12, 2022
RegMed Investors’ (RMi) closing bell: cell and gene therapy sector share pricing rides the roller-coaster
October 11, 2022
RegMed Investors’ (RMi) closing bell: an oversold bounce from nowhere to close neutral in my coverage group
October 11, 2022
RegMed Investors’ (RMi) pre-open: is a short-term bottom close – not by a long-shot?
October 6, 2022
RegMed Investors’ (RMi) closing bell: no, good and bad news makes little difference in sector pricing
October 5, 2022
RegMed Investors’ (RMi) closing bell: another I warned you so …
October 4, 2022
RegMed Investors’ (RMi) closing bell: the cell and gene therapy sector ballooned-up
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.